18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.

doi:10.1158/1078-0432.CCR-25-0279

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2026

Prost Diego, Nichelli Lucia, Rozenblum Laura, Laurenge Alice, Dehais Caroline, Mathon Bertrand, Jacob Julian, Drouiche Louisa, Escamilla-Ramírez Angel, Houillier Caroline, Hoang-Xuan Khê, Sanson Marc, Idbaih Ahmed, Bielle Franck, Branzoli Francesca, Savatovsky Julien, Kas Aurélie, Touat Mehdi

Abstract excerpt

PURPOSE: Small-molecule inhibitors targeting isocitrate dehydrogenase (IDH) 1/2-mutant proteins have demonstrated benefit in IDH1/2-mutant gliomas. However, responses assessed by conventional MRI measurements are infrequent, delayed, and difficult to interpret, highlighting the need for early biomarkers of treatment benefit. In this study, we investigated 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine positron...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dihydroxyphenylalanine

Share to Enzyme Inhibitors

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Magnetic Resonance Imaging

Share to Positron-Emission Tomography

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 41627174
DOI: 10.1158/1078-0432.CCR-25-0279

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.PMID 41627174Read ↗

Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas.Semantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Advanced imaging of IDH-mutant gliomas: Precision in diagnosis and management.Semantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification - a retrospective analysis.Semantic proximity Read ↗

Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomasSemantic proximity Read ↗

Glioma Response to IDH Inhibition: Real-World Experience.Semantic proximity Read ↗

Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.Semantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.Semantic proximity Read ↗

Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.